TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as m… Read more
TME Pharma N.V. (ALTME) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 5.018x
Based on the latest financial reports, TME Pharma N.V. (ALTME) has a cash flow conversion efficiency ratio of 5.018x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.86 Million) by net assets (€-570.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TME Pharma N.V. - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how TME Pharma N.V.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
TME Pharma N.V. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TME Pharma N.V. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aiadvertising Inc
PINK:AIAD
|
0.260x |
|
EMBR3F
SA:EMBR3F
|
N/A |
|
IMAC Holdings Inc
NASDAQ:BACK
|
0.228x |
|
GESCO N - Dusseldorf Stock Exchang
DU:GSC1
|
0.043x |
|
SMITH & NEPHEW (NPW1.SG)
STU:NPW1
|
N/A |
|
GUESS?
BE:GU9
|
0.084x |
|
PERSIMMON PLC - Dusseldorf Stock Exchang
DU:OHP
|
N/A |
|
IA Invest FormueFyn Skandi+
CO:IAIFFS
|
N/A |
Annual Cash Flow Conversion Efficiency for TME Pharma N.V. (2014–2024)
The table below shows the annual cash flow conversion efficiency of TME Pharma N.V. from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €1.61 Million | €-4.63 Million | -2.871x | -114.98% |
| 2023-12-31 | €-294.00K | €-5.63 Million | 19.167x | +100.77% |
| 2022-12-31 | €-1.27 Million | €-12.14 Million | 9.546x | +447.13% |
| 2021-12-31 | €4.50 Million | €-12.38 Million | -2.750x | -305.25% |
| 2020-12-31 | €7.70 Million | €-5.22 Million | -0.679x | -129.36% |
| 2019-12-31 | €-1.85 Million | €-4.29 Million | 2.312x | +50.67% |
| 2018-12-31 | €-2.61 Million | €-4.00 Million | 1.534x | +41.92% |
| 2017-12-31 | €-3.92 Million | €-4.24 Million | 1.081x | -70.15% |
| 2016-12-31 | €-2.48 Million | €-8.99 Million | 3.622x | +88.94% |
| 2015-12-31 | €-7.03 Million | €-13.48 Million | 1.917x | -3.93% |
| 2014-12-31 | €-6.24 Million | €-12.46 Million | 1.996x | -- |